期刊
VACCINES
卷 11, 期 9, 页码 -出版社
MDPI
DOI: 10.3390/vaccines11091504
关键词
Group A Streptococcus (GAS); Streptococcus pyogenes; SpeA; SpeB; vaccine; safety; autoantibodies; rheumatic heart disease (RHD); Sydenham chorea (SC); pediatric autoimmune neuropsychiatric disorder associated with group A streptococci (PANDAS)
This study evaluated the safety of the GAS vaccine candidate VaxiStrep in rabbits and found that it elicited a strong immune response without adverse events or toxicity. The vaccine did not cause autoimmune pathology and did not cross-react with proteins associated with rheumatic heart disease or Sydenham chorea.
Group A streptococcus (GAS) is a global pathogen associated with significant morbidity and mortality for which there is currently no licensed vaccine. Vaccine development has been slow, mostly due to safety concerns regarding streptococcal antigens associated with autoimmunity and related complications. For a GAS vaccine to be safe, it must be ensured that the antigens used in the vaccine do not elicit an antibody response that can cross-react with host tissues. In this study, we evaluated the safety of our GAS vaccine candidate called VaxiStrep in New Zealand White rabbits. VaxiStrep is a recombinant fusion protein comprised of streptococcal pyrogenic exotoxin A (SpeA) and exotoxin B (SpeB), also known as erythrogenic toxins, adsorbed to an aluminum adjuvant. The vaccine elicited a robust immune response against the two toxins in the rabbits without any adverse events or toxicity. No signs of autoimmune pathology were detected in the rabbits' brains, hearts, and kidneys via immunohistochemistry, and serum antibodies did not cross-react with cardiac or neuronal tissue proteins associated with rheumatic heart disease or Sydenham chorea (SC). This study further confirms that VaxiStrep does not elicit autoantibodies and is safe to be tested in a first-in-human trial.
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据